|
(P729) |
NOAC mono therapy in patients with concomitant indications for oral anticoagulation undergoing transcatheter aortic valve replacement |
|
|
N. A. Geis, C. Kiriakou, E. Chorianopoulos, H. A. Katus, R. Bekeredjian (Heidelberg) |
|
(P730) |
Valve performance and safety profile for oral anticoagulation after transfemoral aortic valve implantation |
|
|
F. Woitek, L. Crusius, N. Mangner, S. Haussig, G. Stachel, D. Holzhey, R. Höllriegel, F. W. Mohr, G. C. Schuler, A. Linke (Leipzig) |
|
(P731) |
Predictors Of new heart block requiring pacemaker implantation in patients undergoing transcatheter aortic valve replacement (TAVR) |
|
|
J. Schewel, D. Schewel, M. Schlüter, F. Kreidel, T. Schmidt, H. Alessandrini, M. Schmoeckel, K.-H. Kuck, C. Frerker (Hamburg) |
|
(P732) |
Impact of pulmonary hypertension on in-hospital outcome after surgical or transcatheter aortic valve replacement |
|
|
P. Stachon, A. Gutmann, K. Kaier, H. Reinecke, A. Zirlik, C. von zur Mühlen, L. Frankenstein, M. Zehender, C. Bode, J. Reinöhl (Freiburg im Breisgau, Freiburg, Münster, Heidelberg) |
|
(P733) |
Long-term follow-up after transcatheter aortic valve implantation and durability of transcatheter aortic valves - results of a prospective single center registry |
|
|
S. Haussig, C. Pleißner, M. Zimmer, N. Mangner, F. Woitek, S. Leontyev, D. Holzhey, F. W. Mohr, G. C. Schuler, A. Linke (Leipzig) |
|
(P734) |
Prevalence and relevance of impaired left ventricular function in chronic moderate regurgitation of native aortic valves |
|
|
B. F. Gomes, B. Meder, D. Mereles, H. A. Katus, R. Bekeredjian (Heidelberg) |